Seed round for accredited investors
This page describes a planned raise. It is not an offer to sell securities, and it does not mean an investment will be accepted. Numbers called targets are assumptions. They are not guarantees.
Labs, a genome, a wearable, a chart, and a stack of papers do not add up to one picture of a person. A doctor still has to do that by hand. NRTR keeps doing it as new data comes in, for the person and for the doctor.
The software is free. It uses the data you already have, and it keeps a running picture of your health without you logging everything by hand.
A doctor gets a picture they can work from, instead of chatbot screenshots and wearable graphs.
Sleep, movement, and recovery, collected in the background. We ship it when it is ready, not on a date we picked for a slide.
People pay when they want a deeper starting point: sequencing and a broad lab panel, then hardware that keeps the record current.
What changed. What does not fit. What is missing. What to measure next. That is the product under the apps and the tests.
For a long time, medicine did not have enough data. That is not the problem now. Wearables, labs, genomes, and clinical software are all being bought. Somebody still has to turn that into a decision about one person.
U.S. healthcare spending, about 18% of GDP. That money is already being spent.
of U.S. adults report at least one tracked chronic condition. 51.4% report more than one.
Personalized medicine, estimated at $567.1B in 2024 and projected toward $1.2T by 2033.
46% of U.S. adults report owning a wearable. Physician use of AI moved from 38% in 2023 to 81% in 2026.
WHOOP and Oura are good at body data over time. Trainerize is good at coaching. Abridge and others are putting AI into the visit. Tempus and Owkin connect patient data to research. Recursion and others use AI in drug development. We are not trying to replace them. We want what they already collect in one picture of the person, so a doctor can use it.
The figures above describe the industry, not NRTR. Targets later on this page are our plan. They are not results, and they are not promises.
We do not put the software behind a subscription. More people using it makes it more useful. We make money when someone wants a better starting point, when they buy the wearable, and when a clinic licenses it for their patients.
The planned starting package is whole-genome sequencing and about 129 biomarkers, at $999. The wearable comes after that. We print and ship it when someone orders it, so we are not sitting on a warehouse of hardware. The software stays free.
Longevity, functional, concierge, and specialty practices already buy labs and devices. They can try the product before a contract. When they want it in the clinic, they pay an annual minimum, then more as they add patients, sites, and hardware.
Users, a short list of clinics that might buy, and a product we can actually sell. Paid launch comes after that.
Turn early interest into clinics that are ready to buy, before the paid launch.
Do not hire a big team or spend hard on ads until the same sale works more than once.
One clinic becomes more patients. One site becomes several. Software leads to hardware. A partner conversation becomes a rollout that actually happens.
December 2028 is when we want the later version of that model, Phase 5, in real use.
Dates and year-end numbers are targets from our planning model. They depend on assumptions. They are not a forecast of what will happen.
We are raising $3.5 million on a SAFE.
This close happens before a price is set. It is an uncapped MFN SAFE. No valuation cap, and no discount. MFN means most favored nation: if the main SAFE in this round ends up with better terms, the early SAFE gets those terms too. Committing first does not lock you into a worse deal.
This close has a cap. It is a post-money SAFE. The cap is the highest company value used to work out what percent the money buys, and it includes this round. The target cap is $28 million. I expect the range to land around $25–28 million. There is no discount, so you do not get an extra cut off a later price.
Those terms are the plan, not the final documents. This page is not an offer to sell securities, and it is not a request to buy them. If someone invests, it goes through the process we set with a securities lawyer, including a real check that they are an accredited investor before we take the money.
Tell me who you are and why you think you qualify. After you send it, the pitch video and a call open on this page.
The full pitch video goes here. Until it is up, book the call and I will walk you through it.
Sending this form does not make you an investor, and it does not hold a spot in the round. Before we accept anyone, we have to take real steps to confirm they are accredited. That can be a written confirmation from a broker-dealer, a registered investment adviser, a licensed attorney, or a CPA. A phone call where someone says they qualify is not enough.